{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T02:48:03Z","timestamp":1648608483884},"reference-count":10,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,7,10]]},"DOI":"10.1182\/bloodadvances.2018021071","type":"journal-article","created":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T15:55:52Z","timestamp":1530633352000},"page":"1547-1550","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation"],"prefix":"10.1182","volume":"2","author":[{"given":"Michael A.","family":"Spinner","sequence":"first","affiliation":[{"name":"Division of Oncology, Department of Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjana H.","family":"Advani","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard T.","family":"Hoppe","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Lowsky","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori S.","family":"Muffly","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2018,7,3]]},"reference":[{"issue":"7","key":"2019111616265494900_B1","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1182\/bloodadvances.2017011122","article-title":"Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT?","volume":"2","author":"Peggs","year":"2018","journal-title":"Blood Adv"},{"issue":"7","key":"2019111616265494900_B2","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1182\/bloodadvances.2017011130","article-title":"Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily","volume":"2","author":"Moskowitz","year":"2018","journal-title":"Blood Adv"},{"issue":"12","key":"2019111616265494900_B3","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"issue":"9980","key":"2019111616265494900_B4","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"2019111616265494900_B5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111616265494900_B6","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"19","key":"2019111616265494900_B7","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"14","key":"2019111616265494900_B8","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019111616265494900_B9","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1182\/bloodadvances.2017007716","article-title":"HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity","volume":"1","author":"Spinner","year":"2017","journal-title":"Blood Adv"},{"issue":"10","key":"2019111616265494900_B10","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/13\/1547\/881438\/advances021071.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/13\/1547\/881438\/advances021071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T21:27:02Z","timestamp":1573939622000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/13\/1547\/15945\/Allogeneic-transplantation-using-TLIATG"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,3]]},"references-count":10,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2018,7,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018021071","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,3]]}}}